GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Beneish M-Score
中文

Phibro Animal Health (Phibro Animal Health) Beneish M-Score : -2.76 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.76 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Phibro Animal Health's Beneish M-Score or its related term are showing as below:

PAHC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.39   Max: -1.87
Current: -2.76

During the past 13 years, the highest Beneish M-Score of Phibro Animal Health was -1.87. The lowest was -2.90. And the median was -2.39.


Phibro Animal Health Beneish M-Score Historical Data

The historical data trend for Phibro Animal Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Beneish M-Score Chart

Phibro Animal Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.31 -2.76 -2.36 -2.26 -2.43

Phibro Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.34 -2.43 -2.57 -2.76

Competitive Comparison of Phibro Animal Health's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phibro Animal Health's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Beneish M-Score falls into.



Phibro Animal Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Phibro Animal Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.982+0.528 * 1.0019+0.404 * 0.9192+0.892 * 1.0102+0.115 * 1.0389
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0639+4.679 * -0.049229-0.327 * 1.0033
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $150.6 Mil.
Revenue was 249.943 + 231.349 + 255.049 + 245.673 = $982.0 Mil.
Gross Profit was 78.616 + 67.726 + 76.666 + 75.54 = $298.5 Mil.
Total Current Assets was $586.6 Mil.
Total Assets was $972.7 Mil.
Property, Plant and Equipment(Net PPE) was $239.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $34.8 Mil.
Selling, General, & Admin. Expense(SGA) was $241.3 Mil.
Total Current Liabilities was $187.7 Mil.
Long-Term Debt & Capital Lease Obligation was $480.0 Mil.
Net Income was 1.274 + -8.015 + 11.498 + 10.042 = $14.8 Mil.
Non Operating Income was -7.477 + -6.689 + 2.174 + 0.422 = $-11.6 Mil.
Cash Flow from Operations was 31.558 + 16.199 + 20.238 + 6.259 = $74.3 Mil.
Total Receivables was $151.8 Mil.
Revenue was 244.646 + 232.521 + 255.265 + 239.619 = $972.1 Mil.
Gross Profit was 77.385 + 68.646 + 78.424 + 71.626 = $296.1 Mil.
Total Current Assets was $581.7 Mil.
Total Assets was $961.8 Mil.
Property, Plant and Equipment(Net PPE) was $221.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $33.8 Mil.
Selling, General, & Admin. Expense(SGA) was $224.5 Mil.
Total Current Liabilities was $167.6 Mil.
Long-Term Debt & Capital Lease Obligation was $490.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(150.627 / 982.014) / (151.83 / 972.051)
=0.153386 / 0.156196
=0.982

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(296.081 / 972.051) / (298.548 / 982.014)
=0.304594 / 0.304016
=1.0019

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (586.586 + 238.998) / 972.708) / (1 - (581.689 + 221.881) / 961.833)
=0.151252 / 0.164543
=0.9192

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=982.014 / 972.051
=1.0102

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(33.799 / (33.799 + 221.881)) / (34.844 / (34.844 + 238.998))
=0.132193 / 0.127241
=1.0389

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(241.254 / 982.014) / (224.473 / 972.051)
=0.245673 / 0.230927
=1.0639

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((480.046 + 187.735) / 972.708) / ((490.574 + 167.569) / 961.833)
=0.686517 / 0.684259
=1.0033

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(14.799 - -11.57 - 74.254) / 972.708
=-0.049229

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Phibro Animal Health has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.


Phibro Animal Health Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Phibro Animal Health (Phibro Animal Health) Business Description

Traded in Other Exchanges
Address
300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Executives
Judith Weinstein officer: See Remarks C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran director
Larry Lee Miller officer: Chief Operating Officer 8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio officer: Chief Financial Officer C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman officer: President,North America Region C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim director, officer: Exec. VP, Corporate Strategy 300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras officer: Pres Animal Health & Nutr N.A. 5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim director, 10 percent owner, officer: President and CEO C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc 10 percent owner 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim director GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino officer: SEE REMARKS GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson officer: Chief Financial Officer 7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson director 2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger officer: SVP, Gen Counsel and Corp Sec 41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046

Phibro Animal Health (Phibro Animal Health) Headlines